Development of Silymarin Entrapped Chitosan Phthalate Nanoparticles for Targeting Colon Cancer

Jump To References Section

Authors

  • U. Ubaidulla
     Department of Pharmaceutics, Crescent School of Pharmacy, B. S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600048 ,IN
  • Priyanka Sinha
     Department of Pharmaceutics, Crescent School of Pharmacy, B. S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600048 ,IN
  • T. Sangavi
     Department of Pharmaceutics, Crescent School of Pharmacy, B. S. Abdur Rahman Crescent Institute of Science and Technology, Chennai - 600048 ,IN
  • Grace Rathnam
     Department of Pharmaceutics, Crescent School of Pharmacy, B. S. Abdur Rahman Crescent Institute of Science and Technology, Chenna ,IN

DOI:

https://doi.org/10.18311/jnr/2022/29816

Keywords:

Chitosan Phthalate, Colon Cancer, Design of Experiments (DOE), Nanoparticles, Quality by Design (QbD), Silymarin

Abstract

The present paper deals with the development of silymarin entrapped Chitosan Phthalate (CP) nanoparticles for targeting colon cancer. The QbD approach is applied to optimize the silymarin loaded chitosan phthalate nanoparticles. DOE was employed to evaluate the dependent variables from the responses of CP nanoparticles. The CP NPs were found to be 140% of mucoadhesivity at pH 7.4, superior to pH 1.2 (10%). The result revealed the chemical or ionic bond formation between the positively charged amino groups of chitosan phthalate and the negatively charged sialic acid residue of mucin present in the mucous membrane. In vitro drug release profiles were carried out under acidic and basic pH conditions. The release of encapsulated silymarin was found to be poor in acidic conditions and maximum in basic conditions. The results suggested that chitosan phthalate nanoparticles could have the potential to enhance the bioavailability of silymarin.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2022-12-16

How to Cite

Ubaidulla, U., Sinha, P., Sangavi, T., & Rathnam, G. (2022). Development of Silymarin Entrapped Chitosan Phthalate Nanoparticles for Targeting Colon Cancer. Journal of Natural Remedies, 22(4), 659–671. https://doi.org/10.18311/jnr/2022/29816

Issue

Volume 22, Issue 4, October 2022

Section

Research Articles

License

Copyright (c) 2022 udhumansha ubaidulla

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC
Received 2022-03-16
Accepted 2022-08-10
Published 2022-12-16

 

References

Dixit N, Baboota S, Kohli K, Ahmad S, Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol. 2007; 39(4):172-179. https://doi.org/10.4103/0253-7613.36534 DOI: https://doi.org/10.4103/0253-7613.36534

Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. “Silymarin”, a Promising Pharmacological Agent for Treatment of Diseases. Iran J Basic Med Sci. 2011; 14(4):308- 317.

Abdullah AS, Ibrahim El Tantawy El Sayed, Moneim AA, El-Torgoman, Alghamdi NA, Ullah S, Wageh S. Preparation and Characterization of Silymarin-Conjugated Gold Nanoparticles with Enhanced Anti-Fibrotic Therapeutic Effects against Hepatic Fibrosis in Rats: Role of MicroRNAs as Molecular Targets. Biomedicines. 2021; 9:1767. https:// doi.org/10.3390/biomedicines9121767 DOI: https://doi.org/10.3390/biomedicines9121767

Costanzo AD, Angelico R. Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art. Molecules. 2019; 24:2155. https://doi.org/10.3390/molecules24112155 DOI: https://doi.org/10.3390/molecules24112155

Yang G. Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids. Asian J. Pharma. Sci. 2015; 10(3):194- 202. https://doi.org/10.1016/j.ajps.2014.12.001 DOI: https://doi.org/10.1016/j.ajps.2014.12.001

El-Nahas AE, Allam AN, Abdelmonsif DA, El-Kamel AH. Silymarin-Loaded Eudragit Nanoparticles: Formulation, Characterization, and Hepatoprotective and Toxicity Evaluation. AAPS PharmSciTech. 2017; 18(8):3076-3086. https://doi.org/10.1208/s12249-017-0799-9 DOI: https://doi.org/10.1208/s12249-017-0799-9

Dasari SK, Rathnam G, Ubaidulla U, Ganesh M, Jang HT. Chitosan phthalate: A novel polymer for the multiparticulate drug delivery system for diclofenac sodium. Adv. Polym. Technol. 2018; 37:2013-2020. https://doi.org/10.1002/ adv.21859 DOI: https://doi.org/10.1002/adv.21859

U. Ubaidulla, F. J. Ahmad, R. K. Khar, P Tripathi. Optimization of chitosan succinate and chitosan phthalate microspheres for oral delivery of insulin using response surface methodology. Pharm Dev Technol. 2008; 14(1):99- 108. https://doi.org/10.1080/10837450802409461 DOI: https://doi.org/10.1080/10837450802409461

Sinha P, Udhumansha U, Rathnam G, Ganesh M, Jang HT. Capecitabine Encapsulated Chitosan Succinate-Sodium Alginate Macromolecular Complex Beads For Colon Cancer Targeted Delivery: In Vitro Evaluation. Int. J. Biol. Macromol. 2018; 117:840-850. https://doi.org/10.1016/j. ijbiomac.2018.05.181 DOI: https://doi.org/10.1016/j.ijbiomac.2018.05.181

Ganesh M, Ubaidulla U, Rathnam G, Jang HT. Chitosan- Telmisartan polymeric cocrystals for improving oral absorption: In vitro and in vivo evaluation. Int. J. Biol. Macromol. 2019; 131:879-885. https://doi.org/10.1016/j. ijbiomac.2019.03.141 DOI: https://doi.org/10.1016/j.ijbiomac.2019.03.141